摘要
目的探讨慢性肾脏病(chronic kidney disease,CKD)患者血浆成纤维细胞生长因子23(fibroblast growth factor 23,FGF23)与左心室肥厚(left ventricular hypertrophy, LVH)的相关性。方法选取2016 年10 月~2017 年10 月在川北医学院附属医院肾内科住院的CKD 患者64 例,其中CKD1~2 期16 例;CKD3 期16 例;CKD4 期16 例;CKD5 期16 例;对照组选取同期我院健康体检者32 例。采用酶联免疫吸附方法测定血浆FGF23 水平。经超声心动图测量并计算左心室质量指数(left ventricularmass index,LVMI)。相关分析法分析左心室质量指数与血浆FGF23 和临床资料的相关性。结果①CKD 患者血浆FGF23[(6.74±6.16)ng/ml]显著高于健康对照组[(1.22±0.19)ng/ml],差异具有统计学意义(t=-0.348,P =0.001),且随着CKD 的进展,血浆FGF23 水平逐渐升高,在一定程度上可反映肾脏损害程度;②CKD 患者LVH 发生率39.06%;③Pearson 相关分析显示血浆FGF23 水平与LVMI 呈正相关(r=0.372,P=0.002),是LVH 的独立危险因素;④多元逐步线性回归显示血浆FGF23 是影响LVH 的独立危险因素,差异具有统计学意义(B=0.272,t=2.272,P =0.027),有望成为CKD 患者心血管疾病的治疗靶点,提高CKD 患者生存率。
Objective To explore the correlation between plasma fibroblast growth factor 23 (FGF23) level and left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). Methods Sixty- four CKD patients (16 cases at CKD stages 1~2, 16 cases at CKD stage 3, 16 cases at CKD stage 4, and 16 cases at CKD stage 5) admitted to the Affiliated Hospital of North Sichuan Medical College during October 2016 to October 2017 were recruited in this study. Thirty-two normal individuals in our hospital were selected as the normal controls. Plasma FGF23 was assayed by ELISA method. Left ventricular mass index (LVMI) was calculated from echocardiography. The relationship between plasma FGF23 level, LVMI and clinical data was analyzed by correlation analyses. Results ① Plasma FGF23 was significantly higher in CKD patients than in normal control group (6.74±6.16ng/ml vs. 1.22±0.19ng/ml;t=-0.348, P=0.001). Plasma FGF23 level increased gradually with the development of CKD, suggesting that plasma FGF23 level may reflect the extent of renal damage.②The prevalence of LVH was 39.06% in CKD patients.③ Pearson correlation analysis showed that plasma FGF23 level was positively correlated with LVMI (r=0.372, P=0.002) and was the independent risk factor for LVH.④ Multivariate stepwise linear regression also showed that plasma FGF23 was the independent risk factor for LVMI (B=0.272, t=2.272, P=0.027). Therefore, FGF23 is expected to be a therapeutic target for cardiovascular disease in CKD patients to increase their survival rate.
作者
李美兰
刘晓慧
LI Mei-lan;LIU Xiao-hui(Department of Nephrology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000;Department of Nephrology,People's Hospital of Anyue County,Ziyang 642350,China)
出处
《中国血液净化》
CSCD
2019年第9期622-625,649,共5页
Chinese Journal of Blood Purification
关键词
成纤维细胞生长因子23
左心室肥厚
慢性肾脏病
Fibroblast growth factor 23
Left ventricular hypertrophy
Chronic kidney disease
